Loading
A phase 2 trial of Zilovertamab vedotin, Nemtabrutinib in mantle cell lymphoma and follicular lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) is a phase 2 interventional study registered as NCT05458297 by Merck Sharp & Dohme LLC, with 189 participants planned, started 2022-07-21 and due to reach its primary completion in 2029-05-17. Interventions recorded: Zilovertamab vedotin, Nemtabrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma. No results are recorded here; the registry entry is the source.
Shares Nemtabrutinib, Mantle cell lymphoma, Follicular lymphoma, Merck & Co. (MSD).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Nemtabrutinib, Merck & Co. (MSD).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).